United Statesrevolutionmedicines.com
Revolution Medicines is a clinical-stage biotechnology company focused on developing precision oncology therapies targeting RAS-mutated cancers. The company utilizes its proprietary tri-complex technology to create small molecule inhibitors that bind to the active form of RAS proteins, known as RAS(ON). This approach addresses a significant unmet need in oncology, as RAS mutations are present in about 30 percent of all cancers.
Headquartered in Redwood City, California, the company operates primarily in the United States but conducts clinical trials internationally. Its main activities include drug discovery, preclinical research, and clinical development of its pipeline candidates. Revolution Medicines is publicly traded on the NASDAQ exchange under the ticker symbol RVMD, making it an independent entity in the biotechnology sector.
In the industry, Revolution Medicines is recognized as a pioneer in RAS-targeted therapies, competing with other firms developing similar inhibitors. The company has advanced its lead product, daraxonrasib, into late-stage clinical trials for indications such as metastatic pancreatic cancer, as indicated by its application to the European Medicines Agency for authorization. This positions the firm as an innovative player with potential to impact standard treatments for hard-to-treat cancers.
Also known as RevMed.
None yet. When a new project in the record names Revolution Medicines as owner, partner or investor, it shows here.
CHMP backs an oral RAS inhibitor for adults with metastatic pancreatic adenocarcinoma after prior therapy; phase‑3 data show doubled median survival versus chemotherapy and review took under 150 days.
